Antiseizure Medication Concentrations During Pregnancy Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study

Keyphrases

• During Pregnancy 100%
• Pregnant Women 100%
• Pregnancy Outcome 100%
• Maternal Outcomes 100%
• Antiepileptic Drugs 100%
• Outcome Effect 100%
• Neurodevelopmental Effects 100%
• Drug Studies 100%
• Antiseizure Medication 100%
• Carbamazepine 80%
• Oxcarbazepine 80%
• Normalized Concentration 80%
• Topiramate 60%
• Women with Epilepsy 40%
• Non-pregnant Women 40%
• Levetiracetam 40%
• Median Range 40%
• Lamotrigine 40%
• Zonisamide 40%
• Lacosamide 40%
• Carbamazepine-10,11-epoxide 40%
• Epilepsy 20%
• Pregnancy Disorders 20%
• Course of Pregnancy 20%
• Anticonvulsant 20%
• Clinical Consequences 20%
• Plasma Concentration 20%
• Non-interacting 20%
• Inclusion Criteria 20%
• Increased Dose 20%
• Prospective Observational Study 20%
• Participant Enrollment 20%
• Monotherapy 20%
• Gestational Age 20%
• Phlebotomy 20%
• Postpartum Visit 20%
• Partum 20%
• Therapeutic Drug Monitoring 20%
• Concentration Change 20%
• Blood Concentration 20%
• Total Daily Dose 20%
• Pregnant Women with Epilepsy 20%
• Intelligence Quotient 20%
• Fetal Gestational Age 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Oxcarbazepine 100%
• Anticonvulsive Agent 100%
• Carbamazepine 100%
• Topiramate 75%
• Lamictal 50%
• Zonisamide 50%
• Carbamazepine 10,11 Oxide 50%
• Levetiracetam 50%
• Lacosamide 50%
• Cohort Study 25%
• Monotherapy 25%
• Therapeutic Drug Monitoring 25%

Neuroscience

• Carbamazepine 100%
• Antiseizure Medication 100%
• Anticonvulsant 100%
• Oxcarbazepine 66%
• Topiramate 50%
• Lamotrigine 33%
• Levetiracetam 33%
• Lacosamide 33%
• Epoxide 33%
• Blood Plasma 33%
• Zonisamide 33%